Host Cell Genome

The host cell genome encompasses the complete set of deoxyribonucleic acid (DNA) sequences within a cell, serving as the master blueprint for all biological functions and hereditary traits (NHGRI, 2024). It is organized into chromosomes within the nucleus and also includes mitochondrial DNA, providing the templates necessary for RNA transcription and subsequent protein synthesis (Alberts et al., Molecular Biology of the Cell, 2014). In the context of pharmacology, the genome is a primary target for cytotoxic chemotherapy, which often relies on damaging DNA to trigger apoptosis in rapidly dividing cancer cells (Nature Reviews Cancer, 2021). More recently, the advent of gene therapy and genome editing technologies has enabled the direct modification of the host genome to treat or potentially cure genetic diseases by replacing, knocking out, or repairing defective genes (New England Journal of Medicine, 2023). Despite its therapeutic potential, targeting the genome is associated with significant risks, such as unintended off-target mutations and the potential for long-term genotoxic effects that could lead to secondary cancers (Science, 2022). Because the term refers to the entirety of a cell's genetic material rather than a specific protein or gene, it is generally considered too broad to be a single therapeutic target in standard drug databases.

Other names

Genomic DNANuclear DNACellular GenomeHost DNATotal Cellular DNA

Therapeutic agents interact with the host cell genome through various mechanisms, including covalent DNA binding (alkylation), intercalation between base pairs, induction of double-strand breaks via topoisomerase inhibition, or precise sequence modification using programmable nucleases like CRISPR-Cas9 to correct or disrupt specific genes (National Human Genome Research Institute [NHGRI], 2023; FDA, 2023).